Takeda Pharmaceutical Co Ltd (TKPHF) Equity Income (2018 - 2020)
Takeda Pharmaceutical (TKPHF) posted quarterly Equity Income of $5.3 billion for Q3 2020, up 189.53% quarter-over-quarter from $1.8 billion in Q1 2020.
Takeda Pharmaceutical Co Ltd (TKPHF) Equity Income (2018 - 2020) Analysis & Trends
Takeda Pharmaceutical's Equity Income history runs 3 years deep, the most recent figure standing at $5.3 billion for Q3 2020.
- In Q3 2020, Equity Income changed N/A year-over-year to $5.3 billion; the TTM figure through Sep 2020 stood at $6.5 billion (changed N/A YoY), while the FY2020 annual figure was $1.8 billion, up 560.91% from the prior year.
- Equity Income for Q3 2020 stood at $5.3 billion, up from $1.8 billion in the prior quarter.
- The five-year high for Equity Income was $5.3 billion in Q3 2020, with the low at -$604.7 million in Q1 2018.
- The 3-year median for Equity Income is $911.1 million (2019), against an average of $1.6 billion.
- The sharpest annual moves came in 2019 and 2020: Equity Income surged 100.0% in 2019, then jumped 205331553394.47% in 2020.
- Takeda Pharmaceutical's Equity Income stood at -$604.7 million in 2018, then jumped by 100.0% to $0.89 in 2019, then soared by 594491215228.45% to $5.3 billion in 2020.
- Business Quant data shows TKPHF's Equity Income at $5.3 billion in Q3 2020, $1.8 billion in Q1 2020, and $0.89 in Q1 2019.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 5.28 Bn |
| Mar 31, 2020 | 1.82 Bn |
| Mar 31, 2019 | 0.89 |
| Mar 31, 2018 | -604.65 Mn |